BACKGROUND: Although practice guidelines recommend coronary revascularization for patients with heart failure, the evidence to support this recommendation is weak. The objective of our study was to determine the association of coronary revascularization with survival in patients who have had heart failure. METHODS: Data were obtained from the Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH), a clinical outcome-monitoring initiative that has captured data on all patients undergoing cardiac catheterization in the province of Alberta since 1995. Our study included data from patients with a history of heart failure and with documented coronary artery disease; patients with normal coronary arteries or prior coronary artery bypass grafting (CABG) were excluded. We constructed survival curves and adjusted them by the corrected group prognosis method (incorporating all clinical variables in APPROACH). Propensity scores were used to account for clinical characteristics that could influence the decision to revascularize. RESULTS: A total of 2538 patients (mean age 68 yr, standard deviation [SD] 11 yr, 31% female) underwent revascularization; 1690 patients (mean age 69 [SD 11] yr, 34% female) did not. Crude 1-year mortality was 11.8% among patients who underwent revascularization, compared with 21.6% among those who did not. Adjusted survival curves diverged early and continued up to 7 years of follow-up (hazard ratio 0.50, 95% confidence interval 0.44-0.57). Propensity scores showed improved survival with revascularization across all quintiles of likelihood of revascularization. INTERPRETATION: This new evidence lends support to practice guidelines, which recommend revascularization in patients with heart failure and coronary disease.
BACKGROUND: Although practice guidelines recommend coronary revascularization for patients with heart failure, the evidence to support this recommendation is weak. The objective of our study was to determine the association of coronary revascularization with survival in patients who have had heart failure. METHODS: Data were obtained from the Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH), a clinical outcome-monitoring initiative that has captured data on all patients undergoing cardiac catheterization in the province of Alberta since 1995. Our study included data from patients with a history of heart failure and with documented coronary artery disease; patients with normal coronary arteries or prior coronary artery bypass grafting (CABG) were excluded. We constructed survival curves and adjusted them by the corrected group prognosis method (incorporating all clinical variables in APPROACH). Propensity scores were used to account for clinical characteristics that could influence the decision to revascularize. RESULTS: A total of 2538 patients (mean age 68 yr, standard deviation [SD] 11 yr, 31% female) underwent revascularization; 1690 patients (mean age 69 [SD 11] yr, 34% female) did not. Crude 1-year mortality was 11.8% among patients who underwent revascularization, compared with 21.6% among those who did not. Adjusted survival curves diverged early and continued up to 7 years of follow-up (hazard ratio 0.50, 95% confidence interval 0.44-0.57). Propensity scores showed improved survival with revascularization across all quintiles of likelihood of revascularization. INTERPRETATION: This new evidence lends support to practice guidelines, which recommend revascularization in patients with heart failure and coronary disease.
Authors: P Liu; M Arnold; I Belenkie; J Howlett; V Huckell; A Ignazewski; M H LeBlanc; R McKelvie; J Niznick; J D Parker; V Rao; H Ross; D Roy; S Smith; B Sussex; K Teo; R Tsuyuki; M White; D Beanlands; V Bernstein; R Davies; D Issac; D Johnstone; H Lee; G Moe; G Newton; P Pflugfelder; S Roth; J Rouleau; S Yusuf Journal: Can J Cardiol Date: 2001-12 Impact factor: 5.223
Authors: C Opasich; O Febo; P G Riccardi; E Traversi; G Forni; G Pinna; M Pozzoli; R Riccardi; A Mortara; M Sanarico; F Cobelli; L Tavazzi Journal: Am J Cardiol Date: 1996-08-01 Impact factor: 2.778
Authors: David Joyce; Matthias Loebe; George P Noon; Susan McRee; Robert Southard; Larry Thompson; Christian Skrabal; Keith Youker; Guillermo Torre-Amione Journal: Curr Opin Cardiol Date: 2003-11 Impact factor: 2.161
Authors: S Yusuf; D Zucker; P Peduzzi; L D Fisher; T Takaro; J W Kennedy; K Davis; T Killip; E Passamani; R Norris Journal: Lancet Date: 1994-08-27 Impact factor: 79.321
Authors: Mihai Gheorghiade; James D Flaherty; Gregg C Fonarow; Ravi V Desai; Richard Lee; David McGiffin; Thomas E Love; Inmaculada Aban; Eric J Eichhorn; Robert O Bonow; Ali Ahmed Journal: Int J Cardiol Date: 2010-06-16 Impact factor: 4.164
Authors: Thomas E Vanhecke; Barry A Franklin; Prem Soman; Avijit Lahiri; Jennifer H Mieres; Tina Sias; Dennis A Calnon; David Wolinsky; James E Udelson; Peter A McCullough Journal: Am J Cardiovasc Dis Date: 2011-07-27
Authors: Adam D DeVore; Eric Yow; Mitchell W Krucoff; Matthew W Sherwood; Linda K Shaw; Karen Chiswell; Christopher M O'Connor; Erik Magnus Ohman; Eric J Velazquez Journal: ESC Heart Fail Date: 2019-09-27
Authors: Michał Hawranek; Michal O Zembala; Mariusz Gasior; Tomasz Hrapkowicz; Łukasz Pyka; Daniel Cieśla; Marian Zembala Journal: Oncotarget Date: 2018-04-20